Intravenous Exenatide in Patients With Acute Brain Injury

Inclusion Criteria:

- Adults ≥18 years

- Acute brain injury resulting in admission to the Neurosciences Intensive Care Unit for
an anticipated length of stay >48 hours

- Two Blood glucose concentrations > 150 mg/dL and ≤300 mg/dL

- Informed consent obtained via proxy

Exclusion Criteria:

- Pregnant (verified by urine or serum pregnancy test within 24 hours of initiation of
infusion) or lactating females

- Type 1 diabetes mellitus

- History of pancreatitis or risk factors for acute pancreatitis (i.e ethanol abuse,
gall stones)

- Renal insufficiency defined as creatinine clearance (CrCL) < 45 mL/min

- Known history of gastroparesis

- History of surgery on stomach, esophagus or duodenum

- Diabetic Ketoacidosis or Hyperosmolar Hyperglycemic Nonketotic Syndrome

- Concurrent steroid use or planned post-operative steroid use

- History of organ transplantation

- Brain death or suspected imminent brain death within the next 72 hours

- Refractory intracranial hypertension defined as intracranial pressure (ICP) > 25 mmHg
for greater than 15 minutes and refractory to medical intervention

- Currently enrolled in another investigational drug or device protocol

- Insulin infusion within 3 hours of study drug administration or confirmed long acting
insulin or sulfonylurea use prior to admission within 24 hours of study drug
administration

- Known allergy to exenatide